LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 4 of 15: Mean cell count and mean growth rate across biological replicate 1. - Dataset (ID:20240)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | PF431396 | 3.33 | uM | LJP5 | 72 | hr | 868 | 1354 | 3486 | 0.3886 | 0.1858 |
MDA-MB-231 | PF477736 | 3.33 | uM | LJP5 | 72 | hr | 868 | 1360 | 3486 | 0.3901 | 0.1879 |
MDA-MB-231 | PF562271 | 3.33 | uM | LJP6 | 72 | hr | 868 | 1385 | 3486 | 0.3973 | 0.1974 |
MDA-MB-231 | PHA-665752 | 3.33 | uM | LJP5 | 72 | hr | 868 | 3294 | 3486 | 0.9450 | 0.9268 |
MDA-MB-231 | PHA-793887 | 3.33 | uM | LJP6 | 72 | hr | 868 | 852 | 3486 | 0.2446 | -0.0059 |
MDA-MB-231 | PI103 | 3.33 | uM | LJP6 | 72 | hr | 868 | 1987 | 3486 | 0.5699 | 0.4273 |
MDA-MB-231 | PLX-4720 | 3.33 | uM | LJP5 | 72 | hr | 868 | 2602 | 3486 | 0.7463 | 0.6622 |
MDA-MB-231 | QL-X-138 | 3.33 | uM | LJP6 | 72 | hr | 868 | 1947 | 3486 | 0.5586 | 0.4122 |
MDA-MB-231 | QL-XII-47 | 3.33 | uM | LJP6 | 72 | hr | 868 | 899 | 3486 | 0.2581 | 0.0120 |
MDA-MB-231 | Radicicol | 3.33 | uM | LJP5 | 72 | hr | 868 | 1112 | 3486 | 0.3191 | 0.0933 |
MDA-MB-231 | Radicicol | 3.33 | uM | LJP6 | 72 | hr | 868 | 1277 | 3486 | 0.3664 | 0.1563 |
MDA-MB-231 | Seliciclib | 3.33 | uM | LJP5 | 72 | hr | 868 | 2624 | 3486 | 0.7528 | 0.6709 |
MDA-MB-231 | Ruxolitinib | 3.33 | uM | LJP5 | 72 | hr | 868 | 3306 | 3486 | 0.9484 | 0.9312 |
MDA-MB-231 | XL147 | 3.33 | uM | LJP5 | 72 | hr | 868 | 3611 | 3486 | 1.0358 | 1.0477 |
MDA-MB-231 | Saracatinib | 3.33 | uM | LJP6 | 72 | hr | 868 | 2238 | 3486 | 0.6420 | 0.5233 |
MDA-MB-231 | Selumetinib | 3.33 | uM | LJP6 | 72 | hr | 868 | 1674 | 3486 | 0.4803 | 0.3080 |
MDA-MB-231 | Sirolimus | 3.33 | uM | LJP6 | 72 | hr | 868 | 2839 | 3486 | 0.8143 | 0.7527 |
MDA-MB-231 | Sorafenib | 3.33 | uM | LJP6 | 72 | hr | 868 | 2760 | 3486 | 0.7917 | 0.7226 |
MDA-MB-231 | SU11274 | 3.33 | uM | LJP5 | 72 | hr | 868 | 3127 | 3486 | 0.8970 | 0.8629 |
MDA-MB-231 | Fedratinib | 3.33 | uM | LJP5 | 72 | hr | 868 | 975 | 3486 | 0.2798 | 0.0409 |
MDA-MB-231 | TGX221 | 3.33 | uM | LJP5 | 72 | hr | 868 | 2001 | 3486 | 0.5741 | 0.4329 |
MDA-MB-231 | Torin1 | 3.33 | uM | LJP6 | 72 | hr | 868 | 1210 | 3486 | 0.3472 | 0.1307 |
MDA-MB-231 | Torin2 | 3.33 | uM | LJP5 | 72 | hr | 868 | 1122 | 3486 | 0.3220 | 0.0972 |
MDA-MB-231 | Tozasertib | 3.33 | uM | LJP5 | 72 | hr | 868 | 1128 | 3486 | 0.3235 | 0.0993 |
MDA-MB-231 | Trametinib | 3.33 | uM | LJP5 | 72 | hr | 868 | 1155 | 3486 | 0.3313 | 0.1096 |